Tyra Biosciences, Inc. (TYRA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US90240B1061
Tyra Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -132.76 m USD |
| EBIT | -119.95 m USD |
| Net income | -119.95 m USD |
| Diluted EPS – continuing operations | -2.01 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
More stocks
- DEL MONTE CORP (DMC)
- Nagacorp Ltd (3918.HK)
- Hong Leong Industries Bhd (3301.KL)
- Adtran Networks (ADV.DE)
- Nsfocus Information Technology Co Ltd (300369.SZ)
- GH Research PLC (GHRS)
- HawkEye 360, Inc. (HAWK)
- LA-Z-BOY INC (LZB)
- Hainan Haide Industry Co Ltd (000567.SZ)
- Taiwan FamilyMart Co Ltd (5903.TWO)
- GoodRx Holdings, Inc. (GDRX)
- Moonpig Group PLC (MOON.L)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.